The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19

Evidence from the global outbreak of SARS-CoV-2 has clearly demonstrated that individuals with pre-existing comorbidities are at a much greater risk of dying from COVID-19. This is of great concern for individuals living with these conditions, and a major challenge for global healthcare systems and...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Frontiers in immunology 2020-08, Vol.11, p.1991
Hauptverfasser: Callender, Lauren A, Curran, Michelle, Bates, Stephanie M, Mairesse, Maelle, Weigandt, Julia, Betts, Catherine J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page 1991
container_title Frontiers in immunology
container_volume 11
creator Callender, Lauren A
Curran, Michelle
Bates, Stephanie M
Mairesse, Maelle
Weigandt, Julia
Betts, Catherine J
description Evidence from the global outbreak of SARS-CoV-2 has clearly demonstrated that individuals with pre-existing comorbidities are at a much greater risk of dying from COVID-19. This is of great concern for individuals living with these conditions, and a major challenge for global healthcare systems and biomedical research. Not all comorbidities confer the same risk, however, many affect the function of the immune system, which in turn directly impacts the response to COVID-19. Furthermore, the myriad of drugs prescribed for these comorbidities can also influence the progression of COVID-19 and limit additional treatment options available for COVID-19. Here, we review immune dysfunction in response to SARS-CoV-2 infection and the impact of pre-existing comorbidities on the development of COVID-19. We explore how underlying disease etiologies and common therapies used to treat these conditions exacerbate COVID-19 progression. Moreover, we discuss the long-term challenges associated with the use of both novel and repurposed therapies for the treatment of COVID-19 in patients with pre-existing comorbidities.
doi_str_mv 10.3389/fimmu.2020.01991
format Article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7437504</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_bbf97fbb70424781af0874eed1ba5beb</doaj_id><sourcerecordid>2441610403</sourcerecordid><originalsourceid>FETCH-LOGICAL-c462t-5a8f1566c5ea86f67260bdda83c937f6042d8a83cc56c0de7b7d429e808ab1423</originalsourceid><addsrcrecordid>eNpVkUtP3DAURqOqqCDKvqvKy24y9St2sqlUTSlEQqJCtFvLj-vBKImndoLg39czQxF449d3j691quoTwSvG2u6rD-O4rCimeIVJ15F31QkRgteMUv7-1fq4Osv5HpfBO8ZY86E6ZrTDjEtxUt3c3gHqx622M4oe_UpQw2PIc5g2aB3HmExwYQ6QkZ4cKuGkt7DMwaJ-miE9wDSHOGUUJ7S-_tP_qEn3sTryeshw9jyfVr9_nt-uL-ur64t-_f2qtlzQuW5060kjhG1At8ILSQU2zumW2Y5JLzCnrt3tbCMsdiCNdJx20OJWG8IpO636A9dFfa-2KYw6Pamog9ofxLRROpVOB1DG-E56Y2SBctkS7XErOYAjRjcGTGF9O7C2ixnB2fKtpIc30Lc3U7hTm_igJGeywbwAvjwDUvy7QJ7VGLKFYdATxCUryjkRBHPMShQfojbFnBP4l2cIVjuzam9W7cyqvdlS8vl1ey8F_z2yfzR8oGc</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2441610403</pqid></control><display><type>article</type><title>The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19</title><source>Open Access: DOAJ - Directory of Open Access Journals</source><source>MEDLINE</source><source>PubMed Central</source><source>EZB Electronic Journals Library</source><source>PubMed Central Open Access</source><creator>Callender, Lauren A ; Curran, Michelle ; Bates, Stephanie M ; Mairesse, Maelle ; Weigandt, Julia ; Betts, Catherine J</creator><creatorcontrib>Callender, Lauren A ; Curran, Michelle ; Bates, Stephanie M ; Mairesse, Maelle ; Weigandt, Julia ; Betts, Catherine J</creatorcontrib><description>Evidence from the global outbreak of SARS-CoV-2 has clearly demonstrated that individuals with pre-existing comorbidities are at a much greater risk of dying from COVID-19. This is of great concern for individuals living with these conditions, and a major challenge for global healthcare systems and biomedical research. Not all comorbidities confer the same risk, however, many affect the function of the immune system, which in turn directly impacts the response to COVID-19. Furthermore, the myriad of drugs prescribed for these comorbidities can also influence the progression of COVID-19 and limit additional treatment options available for COVID-19. Here, we review immune dysfunction in response to SARS-CoV-2 infection and the impact of pre-existing comorbidities on the development of COVID-19. We explore how underlying disease etiologies and common therapies used to treat these conditions exacerbate COVID-19 progression. Moreover, we discuss the long-term challenges associated with the use of both novel and repurposed therapies for the treatment of COVID-19 in patients with pre-existing comorbidities.</description><identifier>ISSN: 1664-3224</identifier><identifier>EISSN: 1664-3224</identifier><identifier>DOI: 10.3389/fimmu.2020.01991</identifier><identifier>PMID: 32903476</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>Betacoronavirus - drug effects ; Comorbidity ; Coronavirus Infections - drug therapy ; Coronavirus Infections - mortality ; Coronavirus Infections - pathology ; COVID-19 ; Humans ; Immunology ; immunology and infectious diseases ; inflammation ; inflammatory diseases ; Pandemics ; Pneumonia, Viral - drug therapy ; Pneumonia, Viral - mortality ; Pneumonia, Viral - pathology ; Risk ; Risk Factors ; SARS-CoV-2 ; virus immunity</subject><ispartof>Frontiers in immunology, 2020-08, Vol.11, p.1991</ispartof><rights>Copyright © 2020 Callender, Curran, Bates, Mairesse, Weigandt and Betts.</rights><rights>Copyright © 2020 Callender, Curran, Bates, Mairesse, Weigandt and Betts. 2020 Callender, Curran, Bates, Mairesse, Weigandt and Betts</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c462t-5a8f1566c5ea86f67260bdda83c937f6042d8a83cc56c0de7b7d429e808ab1423</citedby><cites>FETCH-LOGICAL-c462t-5a8f1566c5ea86f67260bdda83c937f6042d8a83cc56c0de7b7d429e808ab1423</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437504/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437504/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,2103,27926,27927,53793,53795</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32903476$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Callender, Lauren A</creatorcontrib><creatorcontrib>Curran, Michelle</creatorcontrib><creatorcontrib>Bates, Stephanie M</creatorcontrib><creatorcontrib>Mairesse, Maelle</creatorcontrib><creatorcontrib>Weigandt, Julia</creatorcontrib><creatorcontrib>Betts, Catherine J</creatorcontrib><title>The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19</title><title>Frontiers in immunology</title><addtitle>Front Immunol</addtitle><description>Evidence from the global outbreak of SARS-CoV-2 has clearly demonstrated that individuals with pre-existing comorbidities are at a much greater risk of dying from COVID-19. This is of great concern for individuals living with these conditions, and a major challenge for global healthcare systems and biomedical research. Not all comorbidities confer the same risk, however, many affect the function of the immune system, which in turn directly impacts the response to COVID-19. Furthermore, the myriad of drugs prescribed for these comorbidities can also influence the progression of COVID-19 and limit additional treatment options available for COVID-19. Here, we review immune dysfunction in response to SARS-CoV-2 infection and the impact of pre-existing comorbidities on the development of COVID-19. We explore how underlying disease etiologies and common therapies used to treat these conditions exacerbate COVID-19 progression. Moreover, we discuss the long-term challenges associated with the use of both novel and repurposed therapies for the treatment of COVID-19 in patients with pre-existing comorbidities.</description><subject>Betacoronavirus - drug effects</subject><subject>Comorbidity</subject><subject>Coronavirus Infections - drug therapy</subject><subject>Coronavirus Infections - mortality</subject><subject>Coronavirus Infections - pathology</subject><subject>COVID-19</subject><subject>Humans</subject><subject>Immunology</subject><subject>immunology and infectious diseases</subject><subject>inflammation</subject><subject>inflammatory diseases</subject><subject>Pandemics</subject><subject>Pneumonia, Viral - drug therapy</subject><subject>Pneumonia, Viral - mortality</subject><subject>Pneumonia, Viral - pathology</subject><subject>Risk</subject><subject>Risk Factors</subject><subject>SARS-CoV-2</subject><subject>virus immunity</subject><issn>1664-3224</issn><issn>1664-3224</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>DOA</sourceid><recordid>eNpVkUtP3DAURqOqqCDKvqvKy24y9St2sqlUTSlEQqJCtFvLj-vBKImndoLg39czQxF449d3j691quoTwSvG2u6rD-O4rCimeIVJ15F31QkRgteMUv7-1fq4Osv5HpfBO8ZY86E6ZrTDjEtxUt3c3gHqx622M4oe_UpQw2PIc5g2aB3HmExwYQ6QkZ4cKuGkt7DMwaJ-miE9wDSHOGUUJ7S-_tP_qEn3sTryeshw9jyfVr9_nt-uL-ur64t-_f2qtlzQuW5060kjhG1At8ILSQU2zumW2Y5JLzCnrt3tbCMsdiCNdJx20OJWG8IpO636A9dFfa-2KYw6Pamog9ofxLRROpVOB1DG-E56Y2SBctkS7XErOYAjRjcGTGF9O7C2ixnB2fKtpIc30Lc3U7hTm_igJGeywbwAvjwDUvy7QJ7VGLKFYdATxCUryjkRBHPMShQfojbFnBP4l2cIVjuzam9W7cyqvdlS8vl1ey8F_z2yfzR8oGc</recordid><startdate>20200811</startdate><enddate>20200811</enddate><creator>Callender, Lauren A</creator><creator>Curran, Michelle</creator><creator>Bates, Stephanie M</creator><creator>Mairesse, Maelle</creator><creator>Weigandt, Julia</creator><creator>Betts, Catherine J</creator><general>Frontiers Media S.A</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20200811</creationdate><title>The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19</title><author>Callender, Lauren A ; Curran, Michelle ; Bates, Stephanie M ; Mairesse, Maelle ; Weigandt, Julia ; Betts, Catherine J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c462t-5a8f1566c5ea86f67260bdda83c937f6042d8a83cc56c0de7b7d429e808ab1423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Betacoronavirus - drug effects</topic><topic>Comorbidity</topic><topic>Coronavirus Infections - drug therapy</topic><topic>Coronavirus Infections - mortality</topic><topic>Coronavirus Infections - pathology</topic><topic>COVID-19</topic><topic>Humans</topic><topic>Immunology</topic><topic>immunology and infectious diseases</topic><topic>inflammation</topic><topic>inflammatory diseases</topic><topic>Pandemics</topic><topic>Pneumonia, Viral - drug therapy</topic><topic>Pneumonia, Viral - mortality</topic><topic>Pneumonia, Viral - pathology</topic><topic>Risk</topic><topic>Risk Factors</topic><topic>SARS-CoV-2</topic><topic>virus immunity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Callender, Lauren A</creatorcontrib><creatorcontrib>Curran, Michelle</creatorcontrib><creatorcontrib>Bates, Stephanie M</creatorcontrib><creatorcontrib>Mairesse, Maelle</creatorcontrib><creatorcontrib>Weigandt, Julia</creatorcontrib><creatorcontrib>Betts, Catherine J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Open Access: DOAJ - Directory of Open Access Journals</collection><jtitle>Frontiers in immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Callender, Lauren A</au><au>Curran, Michelle</au><au>Bates, Stephanie M</au><au>Mairesse, Maelle</au><au>Weigandt, Julia</au><au>Betts, Catherine J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19</atitle><jtitle>Frontiers in immunology</jtitle><addtitle>Front Immunol</addtitle><date>2020-08-11</date><risdate>2020</risdate><volume>11</volume><spage>1991</spage><pages>1991-</pages><issn>1664-3224</issn><eissn>1664-3224</eissn><abstract>Evidence from the global outbreak of SARS-CoV-2 has clearly demonstrated that individuals with pre-existing comorbidities are at a much greater risk of dying from COVID-19. This is of great concern for individuals living with these conditions, and a major challenge for global healthcare systems and biomedical research. Not all comorbidities confer the same risk, however, many affect the function of the immune system, which in turn directly impacts the response to COVID-19. Furthermore, the myriad of drugs prescribed for these comorbidities can also influence the progression of COVID-19 and limit additional treatment options available for COVID-19. Here, we review immune dysfunction in response to SARS-CoV-2 infection and the impact of pre-existing comorbidities on the development of COVID-19. We explore how underlying disease etiologies and common therapies used to treat these conditions exacerbate COVID-19 progression. Moreover, we discuss the long-term challenges associated with the use of both novel and repurposed therapies for the treatment of COVID-19 in patients with pre-existing comorbidities.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>32903476</pmid><doi>10.3389/fimmu.2020.01991</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1664-3224
ispartof Frontiers in immunology, 2020-08, Vol.11, p.1991
issn 1664-3224
1664-3224
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7437504
source Open Access: DOAJ - Directory of Open Access Journals; MEDLINE; PubMed Central; EZB Electronic Journals Library; PubMed Central Open Access
subjects Betacoronavirus - drug effects
Comorbidity
Coronavirus Infections - drug therapy
Coronavirus Infections - mortality
Coronavirus Infections - pathology
COVID-19
Humans
Immunology
immunology and infectious diseases
inflammation
inflammatory diseases
Pandemics
Pneumonia, Viral - drug therapy
Pneumonia, Viral - mortality
Pneumonia, Viral - pathology
Risk
Risk Factors
SARS-CoV-2
virus immunity
title The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T23%3A00%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Impact%20of%20Pre-existing%20Comorbidities%20and%20Therapeutic%20Interventions%20on%20COVID-19&rft.jtitle=Frontiers%20in%20immunology&rft.au=Callender,%20Lauren%20A&rft.date=2020-08-11&rft.volume=11&rft.spage=1991&rft.pages=1991-&rft.issn=1664-3224&rft.eissn=1664-3224&rft_id=info:doi/10.3389/fimmu.2020.01991&rft_dat=%3Cproquest_doaj_%3E2441610403%3C/proquest_doaj_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2441610403&rft_id=info:pmid/32903476&rft_doaj_id=oai_doaj_org_article_bbf97fbb70424781af0874eed1ba5beb&rfr_iscdi=true